semaglutide antibodies GIPR-Ab/GLP-1 peptide–antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice New @NatureMedicine A randomized trial

The 6-month wait is outdated and harmful : Current guidelines requiring 6 months of behavioral therapy before medication lead to high dropout rates (53-70% of early non-responders fail to achieve 5% weight loss) and treatment abandonment

Upon being FDA approved in December 2025, the Wegovy pill became the first version of oral semaglutide (as well as the first oral GLP-1) specifically approved for weight loss

In this Review, we synthesize the current mechanistic understanding of SGLT2 inhibitors and highlight key directions for the future of cardiovascularkidneymetabolic disease management

If youre ready to take your body composition to the next level, peptide therapy could be the missing piece

Brain Journal